Prostate Cancer (PCa) represents the most prevalent malignancy in men and ranks as the second most common cause of death [1]. A significant percentage of patients, ranging from 20% to 50%, will experience disease recurrence, which is characterized by elevated levels of Prostate Specific Antigen (PSA). This state is clinically defined as biochemical recurrence (BCR) (PSA > 0.2 ng/ml) [2]. During BCR, metastases are likely to occur in different anatomical regions. Although rising PSA levels indicate BCR, they do not provide information on the location or extent of the lesions. Consequently, advanced imaging modalities, such as PET/CT are required [3–5]. Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is markedly overexpressed in prostate cancer cells relative to benign tissue. Radiolabeling PSMA with 18F enables the detection of metastatic foci through PET imaging [6,7]. However, false positive results in 18F-PSMA imaging, particularly observed in the ribs and pelvic bones, present significant diagnostic challenges and warrant careful consideration [8].